BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

...of new drugs in dermatology caused in part by large pharmas like Allergan plc and Valeant...
...Sciences Inc., where Chaudhuri was president and CEO. Chaudhuri continued to served as president of Valeant...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

...Center for Molecular Medicine (C3M) and Rachid Benhida of the Institute of Chemistry of Nice (ICN...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...a $650 million follow-on. Were it not for 2017’s $6.5 billion in notes deals by Valeant...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

...Next steps could include investigating the mechanism by which brain lymphatic vessels contribute to MS. Valeant...
BioCentury | Sep 14, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

...potassium channel modulator in development to treat epilepsy, from Bausch Health Companies Inc. (NYSE:BHC; formerly Valeant...
BioCentury | Sep 13, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

...potassium channel modulator in development to treat epilepsy, from Bausch Health Companies Inc. (NYSE:BHC; formerly Valeant...
BioCentury | Aug 3, 2018
Finance

Earnings on deck

...least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant...
BioCentury | Jul 13, 2018
Finance

Pause for politics

...period was aided by $3.8 billion in M&A-related equity raises by Endo International plc and Valeant...
...Ltd. (HKSE:1833), Shanghai, China Shenogen Pharma Group Ltd. Beijing, China State Drug Administration, Beijing, China Valeant...
...Co. Endo International plc I-Mab Biopharma Innovent Biologics Inc. Madrigal Pharmaceuticals Inc. Novavax Inc. Pfizer Inc. Ping An Healthcare and Technology Co. Ltd. Valeant...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...a complete response letter for Furoscix (scFurosemide) to treat edema in patients with heart failure Valeant...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...acid (ETC-1002) / ezetimibe ASCVD Top-line Ph III data August EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) / Valeant...
...NASDAQ:URGN) MitoGel (UGN-101) Low-grade upper tract urothelial carcinoma (UTUC) Top-line Ph III OLYMPUS data 2H18 Valeant...
Items per page:
1 - 10 of 1061
BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

...of new drugs in dermatology caused in part by large pharmas like Allergan plc and Valeant...
...Sciences Inc., where Chaudhuri was president and CEO. Chaudhuri continued to served as president of Valeant...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

...Center for Molecular Medicine (C3M) and Rachid Benhida of the Institute of Chemistry of Nice (ICN...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...a $650 million follow-on. Were it not for 2017’s $6.5 billion in notes deals by Valeant...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

...Next steps could include investigating the mechanism by which brain lymphatic vessels contribute to MS. Valeant...
BioCentury | Sep 14, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

...potassium channel modulator in development to treat epilepsy, from Bausch Health Companies Inc. (NYSE:BHC; formerly Valeant...
BioCentury | Sep 13, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

...potassium channel modulator in development to treat epilepsy, from Bausch Health Companies Inc. (NYSE:BHC; formerly Valeant...
BioCentury | Aug 3, 2018
Finance

Earnings on deck

...least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant...
BioCentury | Jul 13, 2018
Finance

Pause for politics

...period was aided by $3.8 billion in M&A-related equity raises by Endo International plc and Valeant...
...Ltd. (HKSE:1833), Shanghai, China Shenogen Pharma Group Ltd. Beijing, China State Drug Administration, Beijing, China Valeant...
...Co. Endo International plc I-Mab Biopharma Innovent Biologics Inc. Madrigal Pharmaceuticals Inc. Novavax Inc. Pfizer Inc. Ping An Healthcare and Technology Co. Ltd. Valeant...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...a complete response letter for Furoscix (scFurosemide) to treat edema in patients with heart failure Valeant...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...acid (ETC-1002) / ezetimibe ASCVD Top-line Ph III data August EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) / Valeant...
...NASDAQ:URGN) MitoGel (UGN-101) Low-grade upper tract urothelial carcinoma (UTUC) Top-line Ph III OLYMPUS data 2H18 Valeant...
Items per page:
1 - 10 of 1061